Vaccini Covid, Magrini: “More than calm on mix”

On the vaccine mix, the second heterologous vaccine doses, “we must be more than calm”. Aifa director general Nicola Magrini told Rainews24. “In the decisions taken in this phase of the pandemic, less heavy than a few weeks ago, the choice was made – he explained – to avoid that in this phase young populations are potentially offered vaccines that have a very remote risk of a serious event, and therefore safety has been privileged to guarantee maximum safe vaccines for all “. It is a “choice also shared by several countries, so I believe that trust and maximum peace of mind is the message to be given”, he added. At the basis of the heterologous vaccination, Magrini underlined, “there are clinical studies that were carried out with the utmost ethical rigor, but they were not particularly problematic studies. The question was whether there would be more undesirable effects and to what extent, and they are for the more mild or moderate effects. The safety with regard to administration, therefore, is very high “. Even with regard to “long-term safety, that is, whether the vaccine mix is ​​problematic – found Magrini – this is excluded in light of the available data”. Therefore, “having preferred this ‘transfer’ over the second dose for utmost caution was also a mixed principle of fairness to guarantee everyone the best vaccine free of these very rare undesirable effects for which, when the pandemic was very serious, it was instead decided, on the population at greatest risk, to offer a highly effective and also globally safe vaccine “. Compared to whether the Covid-19 vaccines AstraZeneca and Johnson and Johnson are on the same level, “more space was left for J&J that side effects seem less frequent, much less. With the accumulation of data in the world we will see if this vaccine, which is simpler in single doses, can somehow be recovered for special populations in total safety “, said the AIFA general director.